CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor who suffered losses between October 9, 2024, and July 10, 2025, to discuss their legal rights [1]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the company's disclosures regarding its lead cell therapy candidate, deramiocel [2]. - The investigation centers on whether Capricor's board misled investors about the drug's regulatory status and safety data [2]. Group 2: Regulatory Issues - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - The CRL also highlighted outstanding issues in the Chemistry, Manufacturing, and Controls section of the application [3]. Group 3: Stock Performance - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [4].